Trial Profile
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo controlled, Phase 3b Study to Evaluate the Safety and Efficacy of Benralizumab 30 mg sc in Patients with Severe Asthma Uncontrolled on Standard of Care Treatment (ANDHI)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs Benralizumab (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms ANDHI
- Sponsors AstraZeneca; AstraZeneca AB
- 24 May 2023 Results of an analysis assessing rates of clinical remission after treatment with benralizumab in patients with SEA with or without CRSwNP from 5 clinical studies (SIROCCO, CALIMA, ZONDA, ANDHI and PONENTE) presented at the 119th International Conference of the American Thoracic Society
- 24 May 2023 Results (n=378 from studies Andhi-IP and PONENTE) assessing Clinical Remission in Oral Corticosteroid (OCS)-dependent Patients With Severe Asthma presented at the 119th International Conference of the American Thoracic Society
- 24 May 2023 Results from Phase 3b ANDHI in Practice Substudy assessing clinical remission (CR) to evaluate patient remission rates after 6 and 18 months of treatment with benralizumab and percentages of patients who reduced background medications after 18 months presented at the 119th International Conference of the American Thoracic Society